Global Vancomycin Market Size, Share & Trends Report by Type (Daptomycin, Linezolid, Quinupristin, Ampicillin, Chloramphenicol, and Others), By Application (Sepsis, Lung Infection, Skin Soft Tissue Infection, Colitis and Intestinal Inflammation) Forecast (2022-2028)

The global vancomycin market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Vancomycin is a class of medication called glycopeptides antibiotics. It works by preventing bacteria that cause infection. The rise in the prevalence of lung infections such as pneumonia, bronchitis, and others is anticipated to drive the growth of the global vancomycin market. For instance, according to the data published by World Health Organization (WHO) in 2021, pneumonia registers for 14.0% of all mortalities in children under 5 years old, and 740180 mortalities occurred in children in 2019. The WHO states that pneumonia can be protected with simple interventions, and can be treated with low cost, low tech medication, and care. Also, according to the data published by NCBI, pneumonia is the eighth leading cause of mortality and first among infectious causes of mortality. Further, pneumonia varies between 1.5 to 14 cases per 1,000 people and is affected by geography, season, and population characteristics. Thus, vancomycin drugs are anticipated to play a significant role in the treatment of pneumonia, further driving the growth of the market over the forecast period.

Looking towards the demand for vancomycin, key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in October 2020, Xellia Pharmaceuticals had launched new doses of Vanco Readytm (ready to use room temperature premised vancomycin injection bags). The latest strengths of injection are 750mg in 150ml, 1.25g in 250ml, and 1.75g in 350ml. Moreover, Vanco ready is indicated in adults and pediatric patients for the treatment of septicemia and endocarditis.

In May 2019, Hikma Pharmaceutical Plc (Hikma, Group) had launched Vancomycin Hydrochloride for injection in the US. The Vancomycin Hydrochloride for injection is an antibiotic used by healthcare facilities to treat patients who have failed to respond to several antibiotics. The launch aimed to expand the company’s portfolio as well as to provide doctors and hospitals with a broad range of quality medicines to treat the current and future needs of the patients. Thus, such launches are anticipated to drive the growth of the global vancomycin market..

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape– Pfizer Inc., Eli Lilly & Co., Xellia Pharmaceuticals ApS and MGB Biopharma Ltd. among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Vancomycin Market Report by Segment

By Type

• Daptomycin
• Linezolid
• Quinupristin
• Ampicillin
• Chloramphenicol
• Others

By Application

• Lung Infection
• Sepsis
• Soft Skin Tissue Infection
• Colitis and Intestinal Inflammation

Global Vancomycin Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa